Areca Inc. (BCEL) shares have dropped -31.06% to $5.66 in premarket trade on Thursday. BCEL stock gained 7.60% last trading session to finish at $8.21. BCEL stock traded 0.81 million shares, a volume below the average daily volume of 0.95 million shares recorded over the last 50 days. During the last five days, BCEL stock has declined -3.64% but has lost -8.27% over the last one month. Over the last three months, BCEL stock prices have dropped by 32.76 percent, and so far this year -49.16 percent. After presenting preliminary clinical data from a phase 1b trial, BCEL stock is losing ground.
Which BCEL Stock study was that?
Atreca is a biopharmaceutical company developing antibodies derived from an innovative discovery platform. BCEL’s platform allows access to a previously unexplored area in oncology, where immune-system-generated antibodies are targeted by tumors during an immune response. As a result of these antibodies, several first-in-class therapeutic candidates can be developed, one of which is BCEL’s ATRC-101.
Atreca announced today that it had collected its first dose-escalation data in its ongoing Phase 1b study evaluating ATRC-101.
- BCEL data was collected from select types of solid tumors that expressed over 50% of the target in preclinical studies.
- This presentation summarized the findings of BCEL’s first-in-human study of ATRC-101.
- Despite the relatively small number of participants who were heavily pre-treated, BCEL was very pleased with the results so far.
- ATRC-101 targets a new tumor antigen using an innovative mode of action in oncology, developed by BCEL.
- Neither dose-limiting toxicities nor adverse effects were observed with the lead candidate of BCEL in this study.
- At the same time, disease control appears to be associated with ATRC-101 target expression, and the preliminary biomarker analysis agrees with ATRC-101’s proposed mode of action.
- A Phase 1b dose-expansion cohort for ATRC-101 is expected to provide additional data in 2022, as will a combination cohort assessing ATRC-101 and pembrolizumab.
- BCEL plans to conduct additional combinations cohorts testing ATRC-101 with chemotherapy in the near future.
BCEL’s further plans:
With ATRC-101, Atreca (BCEL) offers a new paradigm in cancer research. Based on BCEL’s evaluation of ATRC-101 in a limited number of treatment-refractory patients, the drug developed a favorable safety profile and appears to have a helpful biomarker. BCEL intends to continue research into ATRC-101’s potential for cancer patients.
